Can TScan’s TSC-101 Phase 1 data justify a pivotal leap as TCRX stock falls?
TSC-101 produced rapid donor chimerism with a commercial-ready manufacturing process, but TScan must still prove that the cellular therapy prevents post-transplant relapse.
Pharma & Biotech
Pharma & Biotech
Could zervimesine become the first approved treatment for dementia with Lewy bodies psychosis?
Cognition Therapeutics’ FDA alignment gives zervimesine a clearer pivotal path in dementia with Lewy bodies psychosis, a high-need disorder with no approved therapy
Pharma & Biotech
Could Absci’s ABS-201 open a new biologic pathway for androgenetic alopecia treatment?
Absci’s interim ABS-201 data strengthen the early case for a long-acting PRLR antibody in androgenetic alopecia and AI-designed biologics.
Medical Devices & Diagnostics
One Biosciences advances OneMap platform toward clinical-grade ADC biomarker use
See how One Biosciences is using single-cell profiling to improve ADC biomarkers, patient selection and future companion diagnostics.
Pharma & Biotech
Sigvotatug vedotin Phase 3 miss tests Pfizer’s case for integrin beta-6 targeted ADCs
Discover why Pfizer’s sigvotatug vedotin Phase 3 miss shifts attention to second-line patients, biomarkers and first-line combinations.
Medical Devices & Diagnostics
Galmed buys Colospan as its FDA Breakthrough Device faces a pivotal clinical test
Galmed Pharmaceuticals has acquired Colospan and its CG-100 colorectal bypass device, but European adoption, pivotal United States evidence and financing will determine whether the micro-cap company can create a sustainable medtech business.
Pharma & Biotech
Can Definium turn a 50% stock surge into an FDA path for single-dose depression therapy?
DT120 produced a striking Phase 3 antidepressant effect after one supervised dose, but confirmation, functional unblinding, controlled-substance rules and treatment-site economics remain decisive.
Pharma & Biotech
Antengene, K2 Therapeutics deal signals fresh momentum for solid tumor TCEs
Find out how Antengene’s ATG-106 licensing deal could shape the next phase of solid tumor T cell engager development.
Pharma & Biotech
Why Insilico’s $2.5bn SK Biopharmaceuticals deal could reshape AI drug discovery
Find out how Insilico and SK Biopharmaceuticals are using AI to target neuroimmune CNS disorders in a $2.5B drug discovery pact.
Pharma & Biotech
Why Praxis’ latest FDA win could matter far beyond one genetic epilepsy program
Find out how Praxis’ FDA Breakthrough Therapy Designation for elsunersen could reshape SCN2A-DEE epilepsy treatment and ASO development.